New hope for Tough-to-Treat brain metastases in breast cancer
NCT ID NCT07136428
Summary
This study is testing whether adding a new oral drug called asciminib to the standard treatment trastuzumab can help shrink tumors in the brain for people with HER2+ breast cancer that has spread there. It will first find the safest dose and then see how well the combination works in about 42 patients. Participants will take the pills daily and get IV or injection treatments every 3 weeks until the cancer grows, side effects become too severe, or they choose to stop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2+ METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.